Franck Monnien
Overview
Explore the profile of Franck Monnien including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
411
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abdeljaoued S, Doussot A, Kroemer M, Laloy E, Pallandre J, El Kaddissi A, et al.
Oncoimmunology
. 2025 Jan;
14(1):2455176.
PMID: 39844661
Tissue-resident memory (T) T cells have emerged as key players in cancer immunosurveillance, and their presence has been linked to a favorable clinical outcome in solid cancer patients. Liver metastases...
2.
Truntzer C, Ouahbi D, Huppe T, Rageot D, Ilie A, Molimard C, et al.
Biomedicines
. 2025 Jan;
12(12.
PMID: 39767661
: Pancreatic ductal adenocarcinoma (PDAC) is a cancer with very poor prognosis despite early surgical management. To date, only clinical variables are used to predict outcome for decision-making about adjuvant...
3.
Vial L, Descotes F, Lopez J, Alsugair Z, Ceruse P, Philouze P, et al.
Am J Surg Pathol
. 2024 Nov;
49(1):73-82.
PMID: 39513520
Oncocytic adenocarcinoma (OC) of the salivary glands is a rare and controversial entity. It was recently reclassified as "salivary carcinoma NOS and emerging entities" in the 2022 WHO classification of...
4.
Overs A, Peixoto P, Hervouet E, Molimard C, Monnien F, Durand J, et al.
Clin Epigenetics
. 2024 Oct;
16(1):146.
PMID: 39425144
Background: Colorectal cancer is a public health issue and was the third leading cause of cancer-related death worldwide in 2022. Early diagnosis can improve prognosis, making screening a central part...
5.
Jacquin E, Saunier M, Lepiller Q, Monnien F, Mauny F, Ramanah R, et al.
J Med Virol
. 2024 Sep;
96(9):e29875.
PMID: 39221528
The natural history of cervical cancer is closely linked to that of high-risk human papillomaviruses (HPV) infection. It is recognized that upon HPV DNA integration, partial or complete loss of...
6.
El Kaddissi A, Vernerey D, Falcoz A, Mansi L, Bazan F, Chaigneau L, et al.
Clin Breast Cancer
. 2024 Jul;
24(7):e622-e632.e5.
PMID: 38972830
Context And Aims: Eribulin is used in taxane and anthracycline refractory HER2-negative metastatic breast cancers (MBC). Patients treated in pivotal clinical trials achieved low survival rates, therefore, the identification of...
7.
Saizonou I, Lascombe I, Monnien F, Bedgedjian I, Kleinclauss F, Algros M, et al.
Sci Rep
. 2024 Jul;
14(1):15390.
PMID: 38965292
Non-muscle invasive bladder cancers (NMIBC) pTa-pT1 are depicted by a high risk of recurrence and/or progression with an unpredictable clinical evolution. Our aim was to identify, from the original resection...
8.
DAngelo F, Monnien F, Overs A, Pem I, Dor F, Abad M, et al.
Diagn Pathol
. 2024 Jun;
19(1):88.
PMID: 38909265
Background: HER2-targeted therapies have recently emerged as an option in the management of metastatic colorectal cancer (mCRC) overexpressing HER2. However, data regarding HER2 status in primary CRC and its corresponding...
9.
Schoumacher C, Derangere V, Gaudilliere-Le Dain G, Huppe T, Rageot D, Ilie A, et al.
Oncoimmunology
. 2024 Jan;
13(1):2294563.
PMID: 38169969
Stratification of the prognosis of pancreatic cancer (PDAC) patients treated by surgery is based solely on clinical variables, such as tumor stage and node status. The development of biomarkers of...
10.
Molimard C, Dor F, Overs A, Monnien F, Gessain G, Kedochim L, et al.
Dig Liver Dis
. 2023 Oct;
56(5):853-860.
PMID: 37845155
Background And Aims: In colorectal cancer (CRC), HER2 targeting is a promising treatment and immune infiltrate is an important area of research and strategy. Data regarding HER2 status and immune...